AbbVie has submitted a Biologics License Application to the FDA for etentamig, a second-generation bispecific antibody T-cell engager for relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig demonstrated significant improvements in overall response rate (74.0% vs. 45.7%) and progression-free survival compared to standard therapies. The drug offers a manageable safety profile with monthly dosing, potentially expanding treatment options beyond specialized centers. This submission reflects AbbVie's commitment to advancing multiple myeloma care with therapies that address disease complexity and patient needs across diverse care settings.
AbbVie shares trade at USD 286.30 on Pluang as of Oct 27, 2026 19:12 WIB, down 0.17% in the last day. The stock holds a market cap of $506.70 billion and shows strong investor interest with 88% buy orders. This trading activity occurs alongside AbbVie's recent FDA submission for etentamig, a new treatment for multiple myeloma.
AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-yea...
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
